Rocuronium is more hepatotoxic than succinylcholine in vitro
Authors:
- 1 September 2017
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 34 (9) , 623-627
Abstract
The development of liver failure is a major problem in critically ill patients. The hepatotoxicity of many drugs, as one important reason for liver failure, is poorly screened for in human models. Rocuronium and succinylcholine are neuromuscular blocking agents used for tracheal intubation and for rapid-sequence induction. We used an in-vitro test with a permanent cell line and compared rocuronium and succinylcholine for hepatotoxicity. In-vitro study. A basic science laboratory, University Hospital Rostock, Germany. The basic test compound is the permanent human liver cell line HepG2/C3A. In a standardised microtitre plate assay the toxicity of different concentrations of rocuronium, succinylcholine and plasma control was tested. After two incubation periods of 3 days, the viability of cells (XTT test, lactate dehydrogenase release and trypan blue staining), micro-albumin synthesis and the cytochrome 1A2 activity (metabolism of ethoxyresorufin) were measured. Differences between rocuronium and succinylcholine were assessed using the Kruskal–Wallis one-way test and two-tailed Mann–Whitney U test. Rocuronium, but not succinylcholine, led to a significant dose-dependent decrease of viability, albumin synthesis and cytochrome 1A2 activity of test cells. An in-vitro test with a cell line showed hepatotoxicity of rocuronium that was dose-dependent. Further studies are needed to investigate the underlying mechanisms of the effects of rocuronium on hepatic cellular integrity. Not suitable.Keywords
This publication has 11 references indexed in Scilit:
- Biosensor for Hepatocellular Injury Corresponds to Experimental Scoring of Hepatosplenic Schistosomiasis in MiceBioMed Research International, 2016
- Impaired cell functions of hepatocytes incubated with plasma of septic patientsInflammation Research, 2012
- Preclinical Predictors of Clinical Safety: Opportunities for ImprovementClinical Pharmacology & Therapeutics, 2007
- CHARACTERIZATION OF THE HUMAN HEPATOCELLULAR CARCINOMA (HEPG2) CELL LINE AS AN IN VITRO MODEL FOR CADMIUM TOXICITY STUDIESIn Vitro Cellular & Developmental Biology - Animal, 2004
- Measurement of Succinylcholine Concentration in Human Plasma by Electrospray Tandem Mass SpectrometryAnalytical Biochemistry, 2001
- Rapid Tracheal Intubation with Large-Dose Rocuronium: A Probability-Based ApproachAnesthesia & Analgesia, 2000
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998
- The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosisBritish Journal of Clinical Pharmacology, 1997
- Pilot–Controlled Trial of the Extracorporeal Liver Assist Device in Acute Liver FailureHepatology, 1996
- Repeated Doses of Rocuronium Bromide Administered to Cirrhotic and Control Patients Receiving IsofluraneAnesthesiology, 1996